Centauri Therapeutics Limited Employee Directory
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Centauri Therapeutics Limited is a London-based biotechnology company focused on the discovery and development of novel molecules targeting life-threatening diseases. Its Alphamer technology uses programmable immunity, deploying molecules with one end that binds a pathogen target via an aptamer and another end that presents epitopes to engage circulating antibodies, with the aim of redirecting the antibody response to bacteria. The company notes that its assets include specific leads and platform chemistry protected by intellectual property and a family of granted patents and applications. Centauri reports CTX-187 as its lead clinical candidate advancing toward Phase I studies, and its ABX-01 programme had a clinical candidate announced in March 2025. The firm employs 11-50 people and has reported revenue in the range of $1 million to $10 million.